GET DAILY SIGNALSTriSalus Life Sciences (TLSI) Shares Drop -30% Over 30 Days as Guidance Cuts Mount
Key Takeaways
- TriSalus Life Sciences (TLSI) shares have fallen roughly 30% over the trailing 30 days, extending a multi-month decline that has taken the stock from the low-$5 range to near $2.85.
- The sharpest drop followed third-quarter 2026 results, in which revenue and earnings missed consensus and full-year guidance was cut for the third consecutive quarter.
- Management attributed the shortfall to a slower-than-expected ramp of its expanded sales force and a faster shift toward super-selective Y90 procedures in small distal vessels.
- Positive developments — including FDA clearance of TriNav Advance and favorable CMS reimbursement updates for 2027 — have been outweighed by near-term execution concerns.
- The company remains pre-profitable, ending the third quarter with about $41 million in cash while continuing to fund commercial expansion.
- For additional detail, explore Price Targets, Earnings, and Forecast pages covering TLSI.
Company Background and Market Opportunity
TriSalus Life Sciences is a Westminster, Colorado-based, oncology-focused medical technology company developing delivery technologies and immuno-oncology therapies for difficult-to-treat solid tumors, particularly in the liver and pancreas. Its core commercial product is the TriNav Infusion System, which uses a proprietary Pressure-Enabled Drug Delivery (PEDD) approach to overcome high intratumoral pressure and improve the precision and concentration of therapeutic delivery during tumor embolization procedures.
The company has expanded its portfolio with the TriNav LV, TriGuide guiding catheter, TriNav FLX, and, most recently, TriNav Advance. It is also advancing nelitolimod, an investigational TLR9 agonist immunotherapeutic. Investors follow TLSI for its exposure to a large U.S. addressable market — which management estimates at roughly $2.5 billion across liver embolization and additional indications — as well as its reimbursement catalysts and clinical data pipeline. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Recent Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, TLSI shares have declined approximately 30%, falling from around $4.06 to a closing price near $2.85. The move was punctuated by a single-session drop of roughly 11% after third-quarter earnings, reflecting a clear de-rating as near-term growth expectations were reset.
The quarterly trend is more pronounced. Roughly three months earlier, shares traded near $5.58; the stock has since fallen about 49%. The decline has been steady rather than the result of a single event, as successive guidance reductions and execution concerns progressively weighed on investor sentiment. The current price sits well below the 50-day and 200-day moving averages, signaling sustained downward momentum in the near term.
What Drove the Recent Decline in TLSI Shares
The primary catalyst behind the recent decline was the company's third-quarter 2026 earnings report. Revenue came in at approximately $12.9 million, up 11% year over year and 13% sequentially, but below consensus estimates near $14 million. The company reported a net loss of $0.15 per share, also missing expectations.
More significantly, management lowered full-year 2026 revenue guidance to $46 million to $48 million, implying only 2% to 6% growth, down from a prior range of $54 million to $57 million and an original target of $60 million to $62 million. This marked the third consecutive guidance cut. Executives cited two factors: new sales representatives in expansion territories ramping productivity more slowly than planned, and a faster-than-anticipated shift toward super-selective Y90 administration in small distal vessels that legacy TriNav could not fully address.
Analyst reactions compounded the pressure. H.C. Wainwright lowered its price target to $10 from $12 while maintaining a Buy rating, and Canaccord Genuity set a $4.00 target. Although Citigroup reiterated a Buy recommendation and the company highlighted favorable CMS reimbursement changes, near-term execution concerns dominated trading. From what I see, these adjustments highlight the challenges of scaling in a shifting clinical environment.
Broader Quarterly Pressures and Execution Challenges
The broader three-month decline reflects a repeated pattern of growth expectations being reset downward. After more than doubling its commercial sales footprint in the first half of 2026, the company invested heavily in sales and marketing to capture market share, but new territories have taken longer than expected to reach full productivity.
At the same time, a structural shift in clinical practice — the movement toward super-selective procedures in smaller vessels — temporarily limited the addressable use of the original TriNav device. These headwinds, combined with successive full-year guidance cuts, have eroded investor confidence in the company's near-term growth trajectory, even as gross margin improved to 86% and ordering accounts grew by double digits year over year. One thing that stands out is how these factors interacted to reset expectations.
What to Watch for TLSI Going Forward
Looking ahead, several factors are likely to shape TLSI's stock. The commercial launch and adoption trajectory of TriNav Advance will be closely watched, as the device is designed to address the small-vessel procedures that weighed on third-quarter results. The company's fourth-quarter report should clarify whether the expanded sales organization is converting its growing account base into sustained revenue growth.
Reimbursement developments also matter. CMS finalized a roughly 76% increase in the national Medicare payment for Y90 mapping procedures (C8004), effective January 1, 2027, and established national pricing for office-based lab procedures under G0577. Management has pointed to these changes as foundations for a 2027 acceleration. Investors will also monitor clinical data, including interim PROTECT registry results expected in the first quarter of 2027, as well as any formal 2027 guidance. Macroeconomic conditions affecting small-cap and pre-profit healthcare names may add further volatility. I’m watching this closely for signs of stabilization.
Using AI Tools in My Research Process
In my analysis of names like TLSI, I often turn to Tickeron’s AI Trading Bots to test systematic approaches alongside fundamental review. These tools help surface data-driven strategies that align with different risk profiles and timeframes, providing another lens on potential trading ideas without replacing core due diligence.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Serhii Bondarenko is an AI-focused trading strategist and financial markets analyst specializing in the development and application of AI trading bots and autonomous trading agents. His work combines technical analysis, fundamental analysis, and quantitative research to identify market patterns, forecast price movements, and analyze liquidity, volatility, and correlations across global stock markets. Serhii actively publishes market insights, forecasts, and trading frameworks on platforms such as Investing.com and Finextra, with a strong focus on AI-driven decision-making and next-generation algorithmic trading. His research aims to bridge the gap between traditional trading methodologies and advanced artificial intelligence, helping traders and investors navigate complex and rapidly evolving market conditions.
TLSI's Indicator enters downward trend
The Aroon Indicator for TLSI entered a downward trend on November 10, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 165 similar instances where the Aroon Indicator formed such a pattern. In 139 of the 165 cases the stock moved lower. This puts the odds of a downward move at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TLSI as a result. In 57 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 59%.
The Moving Average Convergence Divergence Histogram (MACD) for TLSI turned negative on November 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 61 similar instances when the indicator turned negative. In 32 of the 61 cases the stock turned lower in the days that followed. This puts the odds of success at 52%.
The 50-day moving average for TLSI moved below the 200-day moving average on November 03, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for TLSI's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
Following a +8.56% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLSI advanced for three days, in 136 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
TLSI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 54 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TLSI's P/B Ratio (30.552) is slightly higher than the industry average of (4.142). P/E Ratio (-2.444) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (5.459) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. TLSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement